The US pharmaceutical industry is at critical policy crossroads, facing a wave of changes that could significantly alter pricing structures, market access dynamics, and global strategy.
In this timely webinar, Simon-Kucher’s pharma experts will examine the implications of recent executive orders, the strategic consequences of tariff measures for pharmaceuticals and the potential re-emergence of Most-Favored-Nation (MFN) pricing.
Participants will gain valuable insights into how these developments may disrupt established commercial models - and how companies can proactively adapt to limit potential impact in the evolving US environment.
Key topics include:
- Executive orders and their impact on US drug pricing frameworks
- Tariff risks and their effect on pharmaceutical imports and supply chains
- The possible return of MFN pricing: Implications for US revenues and global pricing
- Strategic adjustments in market access and launch planning
- Aligning global pricing strategies with shifting US policy
- Future-proofing commercial operations in an uncertain future environment
Join our pharma experts as they break down the intersection of policy, pricing, and performance - and share actionable strategies to stay ahead in a turbulent policy environment.
